Global Blood Therapeutics' Oxbryta Approved Broadly For Sickle Cell Disease
Executive Summary
Oxbryta is the second new drug for sickle cell disease approved in just over one week, but it was approved with a broad label for sickle cell disease while Novartis' Adakveo was approved for pain crises.
You may also be interested in...
S&E Briefs: The Good and The Bad Of COVID-19 On Biotech's Top Line
Regeneron's COVID-19 antibody cocktail helped drive 38% growth for the company, while Global Blood Therapeutics' Oxbryta continues to face headwinds and Horizon focuses on relaunches.
GBT Bucks Gene Therapy Trend With Sanofi Sickle Cell Deal
Building on Oxbryta, which is already approved in the US for the rare blood disorder, Global Blood Therapeutics has licensed two sickle cell disease programs from Sanofi.
Pfizer Ends Pact With GlycoMimetics After SCD Failure
GlycoMimetics’ commercial and pipeline prospects are in doubt after Pfizer terminated their 2011 sickle cell drug development deal, following a failed late-stage study.